XTalks

DECEMBER 10, 2024

Rilzabrutinib joins a wave of innovative ITP therapies , including thrombopoietin-receptor agonists like eltrombopag and romiplostim, which boost platelet production. Rilzabrutinib works by targeting BTK, a protein involved in immune cell communication.

Trials 104

Trials Protein Clinical Development Drugs 104

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Medical Xpress

JANUARY 4, 2023

The researchers found no differences in antibody production, auto-antibodies, T cell profiles, or prior viral exposures, but found elevated levels of spike protein along with increased cytokines (consistent with innate inflammation) and increased troponin (indicating cardiac injury).

Immune Response 90

Immune Response Protein Vaccination Vaccine 90

Pharmaceutical Technology

JUNE 15, 2023

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.

Antibody 130

Antibody Protein Sales Development 130

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. But in this case, Amgen has a fully finished product, he adds. Amgen’s Repatha was greenlit a month later.

Antibody 262

Antibody Drugs Protein Sales 262

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

JANUARY 23, 2023

The introduction of new first-in-class biological therapies will further increase therapy options for SLE and LN patients, and it remains to be seen if any of these products will have superior efficacy and safety profiles to currently available Benlysta, Rituxan, Lupkynis and Saphnelo.

Marketing 278

Marketing Production Drugs Trials 278

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

Research 130

Research Antibody Sales Development 130

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 Lilly has bought into Lycia’s lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological disease and pain.

Protein 69

Protein Licensing Licensing Drugs 69

BioPharma Reporter

MARCH 8, 2022

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a â5m ($5.58m) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourney Biologics S.A.

Protein 52

Protein Antibody Production 52

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

SEPTEMBER 7, 2022

Biopharma companies are under pressure to do more with less in the production of monoclonal antibody (mAb) therapies. However, these processes can damage cells, resulting in more impurities in the downstream process to remove and decreasing the product quality. The first is to increase the specific productivity of the cells.

Protein 130

Protein Production DNA Manufacturing 130

Pharmaceutical Technology

MAY 9, 2023

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is currently being investigated in a Phase I trial as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Drugs 130

Drugs Clinical Development Antibody Protein 130

Scienmag

MAY 26, 2021

A […].

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

The Pharma Data

JANUARY 14, 2021

The FDA has issued straight-to-final guidance that provides sponsors of monoclonal antibody and other therapeutic protein COVID-19 treatments with recommendations for potency assays to ensure consistent product quality. Source link.

Protein 52

Protein Antibody Production Research 52

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. Nuvaxovid demonstrated a significant antibody response when given as a booster dose after primary vaccination with other authorised Covid-19 doses in the COV-BOOST trial.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Pharmaceutical Technology

DECEMBER 7, 2022

Researchers are also investigating blood-based biomarkers to bolster efforts to find Alzheimer’s drugs that go beyond targeting the amyloid protein, so new targets can be tackled, potentially widening the pool of patients who may respond to a therapy. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Pharmaceutical Technology

SEPTEMBER 13, 2022

The multi-year investment, covering the development of drug substances as well as drug products, will be implemented across the current locations of the company in Switzerland, Austria and Slovenia. For this purpose, the company will create a completely integrated scientific environment.

Antibody 130

Antibody Development Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 17, 2023

The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody. It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

Pharmaceutical Technology

JUNE 14, 2023

China’s National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Soliris (eculizumab) to treat refractory generalised myasthenia gravis (gMG) in adult patients. Soliris is a first-in-class C5 complement inhibitor indicated for patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Antibody 130

Antibody Protein Trials Production 130

Pharmaceutical Technology

DECEMBER 7, 2022

Researchers are also investigating blood-based biomarkers to bolster efforts to find Alzheimer’s drugs that go beyond targeting the amyloid protein, so new targets can be tackled, potentially widening the pool of patients who may respond to a therapy. Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

Pharmaceutical Technology

FEBRUARY 19, 2023

It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). The company develops its pipeline products through the Xpress CF and XpressCF+ platform, a biochemical protein synthesis system that develops therapeutic proteins and discovers drugs for the treatment and prevention of diseases.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. The scientists are confident of the efficiency of the new product. 1 (Gamma) and P.2 2 variants. .

Antibody 52

Antibody Protein Scientist Clinical Trials 52

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pharmaceutical Technology

SEPTEMBER 2, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting expanded conditional marketing authorization (CMA) for Novavax ’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), as a booster in adults aged 18 years and above.

Vaccination 147

Vaccination Vaccine Trials Clinical Trials 147

Pharmaceutical Technology

MAY 11, 2023

Approved as the first and only long-acting C5 complement inhibitor, Ultomiris is indicated to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD in the European Union (EU). It inhibits the C5 protein in the terminal complement cascade, part of the body’s immune system.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. According to pre-clinical findings, a booster dose of this vaccine elicited a robust neutralising antibody response against the variants Omicron BA.1,

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Tafamidis is thought to work by stabilising the misfolded proteins.

Antibody 116

Antibody Licensing Licensing Protein 116

Pharmaceutical Technology

APRIL 4, 2023

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for AstraZeneca ’s Ultomiris (ravulizumab) to treat neuromyelitis optica spectrum disorder (NMOSD) in adult patients.

Marketing 130

Marketing Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

FEBRUARY 7, 2023

The human monoclonal antibody denosumab has been designed to bind to osteoclasts activator, RANKL protein. It decreases the osteoclast’s production and activity by attaching to and inhibiting RANKL. This results in bone loss reduction and the likelihood of fractures and other serious conditions related to bones.

Packaging 130

Packaging Packaging Medicine Licensing 130

Pharmaceutical Technology

DECEMBER 6, 2022

In the partnership’s discovery phase, RAVEN, an artificial intelligence (AI) platform of Evaxion will be leveraged for designing a next-generation vaccine candidate that induces cellular as well as humoral/antibody responses. Using ExpreS 2 ion’s ExpreS2 platform, the company will manufacture the antigen constructs obtained from RAVEN.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. The product is designed for the prevention and treatment of COVID-19, along with related coronaviruses. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states.

Vaccination 138

Vaccination Vaccine Development Immune Response 138